Lymphoma, B-Cell
Conditions
Brief summary
The autograft of patients with prognostically unfavourable B-cells lymphoma cells in first remission remains controversial, in particular since the association of Rituximab with chemotherapy. Even though many randomized and non-randomized studies have been conducted, their is still no standard procedure . Recently, the use of early TEP (positron emission topography) answer, after 2 in 3 cures of chemotherapy allowed to select the poor-responder patients who remain candidate to autograft in front-line. Nevertheless, in good-responder patients, the benefits of an intensification therapy ins term of long-lasting disease control remains discussion. This institutional retrospective study aims at comparing the outcome of early metabolic responder patients who received an intensification treatment to those who received a standard chemotherapy.
Interventions
PROCEDUREAutograft
Autograft
Sponsors
Institut Paoli-Calmettes
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with High Risk Big B Cells Lymphoma * Age \> 18 years
Exclusion criteria
* Not applicable
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Compare the survival without progress of transplanted patients versus not transplanted patients | From the date of complete remission post C2 of chemotherapy up to 120 months | Medical follow up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative Relapse Incidence | From the date of complete remission post C2 of chemotherapy up to 120 months | Medical follow up |
| Overall survival | From the date of complete remission post C2 of chemotherapy up to 120 months | Medical follow up |
Countries
France
Outcome results
None listed